Human CCL20/MIP-3 alpha ELISA Kit (Colorimetric)
货号：
NBP2-31049 基本售价：
3648.5 元 规格：
1 Kit
产品信息
概述| 货号 | NBP2-31049 |
| 反应种属 | HuSpecies Glossary |
| 应用 | ELISA |
性能| 供应商 | Novus |
| 免疫原 | Human CCL20/MIP-3alpha ActivELISA |
| 背景 | CCL20/MIP-3Alpha is a small cytokine of the CC chemokine family. It acts as a chemotactic factor that attracts lymphocytes and, slightly, neutrophils, but not monocytes. It is implicated in the formation and function of mucosal lymphoid tissues via chemoattraction of lymphocytes and dendritic cells towards the epithelial cells surrounding these tissues. It is expressed constitutively by keratinocytes in epidermal layers of the skin, intestinal mucosa, epithelial crypts of tonsils, and the epithelium of Payers patches in the intestine (Hoover DM, et al, 2002). MIP-3Alpha triggers an adaptive immune response primarily by attracting immature dendritic cells expressing CCR6 on their surfaces to the site of inflammation, and allows the dendritic cell to take up a foreign antigen and to mature. After binding, CCR6 expression is down-regulated, causing the dendritic cell to migrate to the lymph nodes, where it binds via CCR7 and presents the antigen to CD8 T cells. Thus, it forms a bridge between innate and adaptive immune response (Serafini, et al, 2002). MIP-3Alpha plays an immense role in various cancer entities, such as leukemia, lymphoma, melanoma, hepatocellular carcinoma, prostate cancer, colorectal adenocarcinoma and lung and oral squamous cell carcinoma (Ghadjar P, et al, 2006, 2008). MIP-3Alpha along with its corresponding receptor CCR6 is significantly up-regulated in patients with pancreatic cancer. But inhibition of CCR6 signaling or neutralization of MIP-3Alpha or inhibition of its production and activity may be useful in preventing further progression of the disease and may be a future basic treatment strategy in the management of pancreatic cancer (Campbell AS, et al, 2005). |
| 存放说明 | Storage is content dependent. |
